A new generalization of Weibull distribution with application to a breast cancer data set.
In this article, we propose a new generalization of the Weibull distribution, which incorporates the exponentiated Weibull distribution introduced by Mudholkar and Srivastava (IEEE Trans. Reliab. 1993; 42:299-302) as a special case. We refer to the new family of distributions as the beta-Weibull distribution. We investigate the potential usefulness of the beta-Weibull distribution for modeling censored survival data from biomedical studies. Several other generalizations of the standard two-parameter Weibull distribution are compared with regards to maximum likelihood inference of the cumulative incidence function, under the setting of competing risks. These Weibull-based parametric models are fit to a breast cancer data set from the National Surgical Adjuvant Breast and Bowel Project. In terms of statistical significance of the treatment effect and model adequacy, all generalized models lead to similar conclusions, suggesting that the beta-Weibull family is a reasonable candidate for modeling survival data.
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA. waheda@edc.pitt.edu
Abdus S
AS
Wahed
The Minh
TM
Luong
Jong-Hyeon
JH
Jeong
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001699:Biometry / Q000379:methods*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D016208:Databases, Factual / Q000706:statistics & numerical data*; D018572:Disease-Free Survival; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016013:Likelihood Functions; D008727:Methotrexate / Q000008:administration & dosage; D015233:Models, Statistical; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012307:Risk Factors; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage; D014481:United States / Q000453:epidemiology
D020847:Estrogen Receptor Modulators; D013629:Tamoxifen; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate